PDS Biotechnology Key Executives
This section highlights PDS Biotechnology's key executives, including their titles and compensation details.
Find Contacts at PDS Biotechnology
(Showing 0 of )
PDS Biotechnology Earnings
This section highlights PDS Biotechnology's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-27 | $-0.29 | $-0.21 |
| Read Transcript | Q3 | 2024 | 2024-11-14 | $-0.29 | $-0.29 |
| Read Transcript | Q4 | 2023 | 2024-03-27 | $-0.39 | $-0.34 |
| Read Transcript | Q3 | 2023 | 2023-11-14 | $-0.42 | $-0.35 |
| Read Transcript | Q2 | 2023 | 2023-08-14 | $-0.37 | $-0.37 |
| Read Transcript | Q1 | 2023 | 2023-05-15 | $-0.31 | $-0.32 |
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
$1.25
Stock Price
$56.74M
Market Cap
24
Employees
Florham Park, NJ
Location
Financial Statements
Access annual & quarterly financial statements for PDS Biotechnology, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $57.33K | $49.08K | $246.39K | $176.29K |
| Gross Profit | $- | $-57.33K | $-49.08K | $-246.39K | $-176.29K |
| Gross Profit Ratio | 0.00% | - | - | - | - |
| Research and Development Expenses | $22.57B | $27.76M | $29.43M | $11.25M | $7.92M |
| General and Administrative Expenses | $13.76B | $15.02M | $12.24M | $10.18M | $6.96M |
| Selling and Marketing Expenses | $- | $264.00K | $- | $- | $- |
| Selling General and Administrative Expenses | $13.76B | $15.28M | $12.24M | $10.18M | $6.96M |
| Other Expenses | $- | $0 | $- | $- | $15.61K |
| Operating Expenses | $36.32B | $43.05M | $41.67M | $21.44M | $14.90M |
| Cost and Expenses | $- | $43.05M | $41.67M | $21.44M | $14.90M |
| Interest Income | $2.51B | $2.90M | $935.18K | $4.35K | $55.01K |
| Interest Expense | $-4.67B | $4.21M | $1.32M | $- | $- |
| Depreciation and Amortization | $6.83B | $57.33K | $49.08K | $246.39K | $176.29K |
| EBITDA | $-36.32B | $-40.08M | $-41.62M | $-21.19M | $-14.67M |
| EBITDA Ratio | - | - | - | - | - |
| Operating Income | $-36.32B | $-43.05M | $-41.67M | $-21.44M | $-14.90M |
| Operating Income Ratio | - | - | - | - | - |
| Total Other Income Expenses Net | $-2.16B | $-1.30M | $-381.34K | $4.35K | $55.01K |
| Income Before Tax | $-38.48B | $-44.35M | $-42.05M | $-21.43M | $-14.85M |
| Income Before Tax Ratio | - | - | - | - | - |
| Income Tax Expense | $869.17M | $-1.41M | $-1.20M | $-4.52M | $-135.68K |
| Net Income | $-39.35B | $-42.94M | $-40.85M | $-16.92M | $-14.85M |
| Net Income Ratio | - | - | - | - | - |
| EPS | $-1079.45 | $-1.39 | $-1.43 | $-0.66 | $-0.89 |
| EPS Diluted | $-1079.45 | $-1.39 | $-1.43 | $-0.66 | $-0.89 |
| Weighted Average Shares Outstanding | 36.45M | 30.95M | 28.60M | 25.60M | 16.75M |
| Weighted Average Shares Outstanding Diluted | 36.45M | 30.95M | 28.60M | 25.60M | 16.75M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $15.13K | $14.40K | $14.40K | $14.40K | $74.66K | $74.37K | $11.57K | $97.67K | $60.26K | $60.34K | $61.21K | $61.53K | $61.53K | $62.12K | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-15.13K | $-14.40K | $-14.40K | $-14.40K | $-74.66K | $-74.37K | $-11.57K | $-97.67K | $-60.26K | $-60.34K | $-61.21K | $-61.53K | $-61.53K | $-62.12K | $- | $- | $- | $- |
| Gross Profit Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $4.53M | $6.80M | $4.53M | $6.70M | $7.47M | $6.45M | $8.00M | $5.84M | $16.16M | $4.35M | $3.76M | $5.16M | $3.39M | $3.69M | $2.76M | $1.41M | $2.48M | $2.06M | $1.41M | $1.97M |
| General and Administrative Expenses | $2.83M | $3.37M | $4.16M | $3.39M | $2.94M | $4.07M | $4.69M | $3.58M | $2.67M | $2.93M | $3.33M | $3.32M | $2.93M | $3.27M | $2.34M | $1.64M | $1.53M | $1.85M | $1.52M | $2.06M |
| Selling and Marketing Expenses | $- | $- | $- | $-14.40K | $-14.40K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $2.83M | $3.37M | $4.16M | $3.38M | $2.93M | $4.07M | $4.69M | $3.58M | $2.67M | $2.93M | $3.33M | $3.32M | $2.93M | $3.27M | $2.34M | $1.64M | $1.53M | $1.85M | $1.52M | $2.06M |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $15.61M | $- | $- | $- |
| Operating Expenses | $7.36M | $10.18M | $8.68M | $10.08M | $10.39M | $10.52M | $12.70M | $9.42M | $18.82M | $7.28M | $7.09M | $8.48M | $6.32M | $6.96M | $5.11M | $3.05M | $4.03M | $3.91M | $2.94M | $4.03M |
| Cost and Expenses | $7.36M | $10.18M | $8.68M | $10.10M | $10.41M | $10.52M | $12.70M | $9.42M | $18.82M | $7.28M | $7.09M | $8.48M | $6.32M | $6.96M | $5.11M | $3.05M | $4.03M | $3.91M | $2.94M | $4.03M |
| Interest Income | $503.94K | $666.77K | $675.21K | $668.89K | $683.54K | $739.40K | $750.65K | $729.34K | $854.93K | $145 | $74.55K | $5.70K | $1.73K | $1.36K | $604 | $655 | $764 | $1.21K | $6.62K | $46.42K |
| Interest Expense | $1.10M | $1.21M | $1.19M | $1.17M | $1.17M | $1.07M | $995.40K | $966.85K | $1.25M | $145.25K | $74.55K | $5.70K | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $5.46K | $15.13K | $15.13K | $14.40K | $14.40K | $14.40K | $74.66K | $74.37K | $11.57K | $97.67K | $60.26K | $60.34K | $61.21K | $61.53K | $61.53K | $62.12K | $3.90K | $-37.90K | $45.70K | $3.90K |
| EBITDA | $-6.85M | $-9.50M | $-7.99M | $-9.41M | $-9.71M | $-9.77M | $-11.87M | $-8.62M | $-18.81M | $-7.18M | $-6.96M | $-8.41M | $-6.32M | $-6.96M | $-5.10M | $-3.05M | $-4.02M | $-3.90M | $-2.93M | $-4.03M |
| EBITDA Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $-7.36M | $-10.18M | $-8.68M | $-10.10M | $-10.41M | $-10.52M | $-12.70M | $-9.42M | $-18.82M | $-7.28M | $-7.09M | $-8.48M | $-6.32M | $-6.96M | $-5.11M | $-3.05M | $-4.03M | $-3.91M | $-2.94M | $-4.03M |
| Operating Income Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $-591.78K | $-547.96K | $-512.76K | $-505.85K | $-491.25K | $-329.48K | $-244.74K | $-237.50K | $-316.33K | $-145.25K | $74.55K | $5.70K | $1.73K | $1.36K | $604 | $655 | $764 | $1.21K | $6.62K | $46.42K |
| Income Before Tax | $-7.95M | $-10.73M | $-9.20M | $-10.60M | $-10.90M | $-10.85M | $-12.94M | $-9.66M | $-19.14M | $-7.42M | $-7.02M | $-8.47M | $-6.32M | $-6.96M | $-5.11M | $-3.05M | $-4.03M | $-3.91M | $-2.93M | $-3.99M |
| Income Before Tax Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $- | $- | $-869.17K | $5 | $2 | $-4.73K | $-1.41M | $-3.15K | $2.40M | $-97.67K | $-1.20M | $-5.70K | $4.52M | $-60.26K | $-4.52M | $-60.26K | $-3.14K | $39.11K | $6.62K | $46.42K |
| Net Income | $-7.95M | $-10.73M | $-8.33M | $-10.60M | $-10.90M | $-10.85M | $-11.53M | $-9.66M | $-21.54M | $-7.42M | $-5.82M | $-8.47M | $-6.32M | $-6.96M | $-588.93K | $-3.05M | $-4.03M | $-3.91M | $-2.93M | $-3.99M |
| Net Income Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $-0.22 | $-0.29 | $-0.23 | $-0.30 | $-0.34 | $-0.35 | $-0.37 | $-0.32 | $-0.75 | $-0.26 | $-0.20 | $-0.32 | $-0.22 | $-0.24 | $-0.03 | $-0.14 | $-0.26 | $-0.21 | $-0.19 | $-0.39 |
| EPS Diluted | $-0.22 | $-0.29 | $-0.23 | $-0.30 | $-0.34 | $-0.35 | $-0.37 | $-0.32 | $-0.75 | $-0.26 | $-0.20 | $-0.32 | $-0.22 | $-0.24 | $-0.03 | $-0.14 | $-0.26 | $-0.21 | $-0.19 | $-0.39 |
| Weighted Average Shares Outstanding | 36.63M | 36.81M | 36.69M | 34.82M | 31.67M | 30.91M | 30.80M | 30.43M | 28.77M | 28.46M | 28.45M | 26.16M | 28.43M | 28.43M | 23.16M | 22.26M | 15.36M | 18.96M | 15.36M | 10.31M |
| Weighted Average Shares Outstanding Diluted | 36.63M | 36.81M | 36.69M | 34.82M | 31.67M | 30.91M | 30.80M | 30.43M | 28.77M | 28.46M | 28.45M | 26.16M | 28.43M | 28.43M | 23.16M | 22.26M | 15.36M | 18.96M | 15.36M | 10.31M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $41.69B | $56.56M | $73.82M | $65.24M | $28.84M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $41.69B | $56.56M | $73.82M | $65.24M | $28.84M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $3.36B | $2.49M | $2.66M | $1.60M | $1.50M |
| Total Current Assets | $45.05B | $59.06M | $76.48M | $66.84M | $30.34M |
| Property Plant Equipment Net | $304.21K | $335.00K | $527.53K | $357.70K | $553.15K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $303.91M | $- | $0 | $0 | $-0 |
| Total Non-Current Assets | $304.21M | $335.00K | $527.53K | $357.70K | $553.15K |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $45.36B | $59.39M | $77.01M | $67.20M | $30.89M |
| Account Payables | $1.68M | $6.98M | $1.22M | $1.31M | $1.42M |
| Short Term Debt | $12.56B | $4.22M | $288.04K | $258.92K | $119.90K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $4.52B | $2.42M | $8.31M | $2.19M | $1.74M |
| Total Current Liabilities | $17.09B | $13.63M | $9.82M | $3.76M | $3.27M |
| Long Term Debt | $9.27M | $19.63M | $23.18M | $231.43K | $490.35K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $9.26B | $- | $- | $- | $- |
| Total Non-Current Liabilities | $9.27B | $19.63M | $23.18M | $231.43K | $490.35K |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $26.35B | $33.26M | $33.01M | $3.99M | $3.76M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $12.54K | $10.92K | $9.96K | $9.39K | $7.35K |
| Retained Earnings | $-182.11B | $-144.50M | $-101.56M | $-60.70M | $-43.79M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $0 | $0 | $0 |
| Other Total Stockholders Equity | $201.12B | $170.62M | $145.55M | $123.90M | $70.91M |
| Total Stockholders Equity | $19.00B | $26.13M | $44.00M | $63.21M | $27.13M |
| Total Equity | $19.00B | $26.13M | $44.00M | $63.21M | $27.13M |
| Total Liabilities and Stockholders Equity | $45.36B | $59.39M | $77.01M | $67.20M | $30.89M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $45.36B | $59.39M | $77.01M | $67.20M | $30.89M |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $12.62B | $23.85M | $23.47M | $490.35K | $610.26K |
| Net Debt | $-29.07B | $-32.71M | $-50.35M | $-64.75M | $-28.23M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $41.69M | $49.75M | $57.73M | $66.63M | $56.56M | $54.25M | $60.62M | $65.20M | $73.82M | $71.64M | $52.98M | $58.88M | $65.24M | $69.74M | $74.75M | $25.04M | $28.84M | $33.47M | $16.93M | $21.04M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $41.69M | $49.75M | $57.73M | $66.63M | $56.56M | $54.25M | $60.62M | $65.20M | $73.82M | $71.64M | $52.98M | $58.88M | $65.24M | $69.74M | $74.75M | $25.04M | $28.84M | $33.47M | $16.93M | $21.04M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $3.36M | $2.38M | $2.43M | $2.05M | $2.49M | $2.59M | $2.73M | $2.77M | $2.66M | $2.77M | $2.76M | $1.85M | $1.60M | $1.60M | $2.19M | $2.22M | $1.50M | $373.39K | $2.51M | $2.88M |
| Total Current Assets | $45.05M | $52.13M | $60.16M | $68.69M | $59.06M | $56.84M | $63.35M | $67.97M | $76.48M | $74.41M | $55.74M | $60.73M | $66.84M | $71.34M | $76.93M | $27.26M | $30.34M | $33.84M | $19.44M | $23.92M |
| Property Plant Equipment Net | $304.21K | $319.34K | $334.47K | $320.60K | $335.00K | $349.41K | $403.30K | $475.26K | $527.53K | $475.42K | $258.19K | $308.33K | $357.70K | $407.21K | $456.34K | $504.78K | $553.15K | $602.92K | $652.08K | $17.15K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $- | $-1 | $-1 | $-0 | $-0 | $0 | $0 | $-0 | $0 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Assets | $304.21K | $319.34K | $334.47K | $320.60K | $335.00K | $349.41K | $403.30K | $475.26K | $527.53K | $475.42K | $258.19K | $308.33K | $357.70K | $407.21K | $456.34K | $504.78K | $553.15K | $602.92K | $652.08K | $17.15K |
| Other Assets | $- | $- | $- | $1 | $1 | $- | $- | $- | $- | $-0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $45.36M | $52.45M | $60.50M | $69.01M | $59.39M | $57.19M | $63.75M | $68.45M | $77.01M | $74.89M | $56.00M | $61.04M | $67.20M | $71.75M | $77.39M | $27.76M | $30.89M | $34.45M | $20.09M | $23.93M |
| Account Payables | $1.68M | $1.30M | $3.25M | $6.00M | $6.98M | $5.37M | $4.41M | $2.07M | $1.22M | $2.04M | $1.88M | $2.75M | $1.31M | $1.45M | $2.38M | $950.60K | $1.42M | $1.56M | $1.09M | $2.56M |
| Short Term Debt | $12.56M | $12.56M | $10.48M | $7.35M | $4.22M | $54.54K | $112.96K | $199.09K | $288.04K | $375.25K | $335.01K | $311.31K | $258.92K | $207.72K | $157.66K | $123.65K | $119.90K | $116.24K | $112.66K | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $-3.73B | $-3.37B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $20.78M | $-116.24K | $1.19M | $- |
| Other Current Liabilities | $2.84M | $4.48M | $1.95M | $1.71M | $2.42M | $3.73M | $3.38M | $1.86M | $8.31M | $2.43M | $2.30M | $1.96M | $2.19M | $1.92M | $1.47M | $1.85M | $1.74M | $1.22M | $1.32M | $1.49M |
| Total Current Liabilities | $17.09M | $18.34M | $15.67M | $15.06M | $13.63M | $9.15M | $7.90M | $4.13M | $9.82M | $4.84M | $4.52M | $5.02M | $3.76M | $3.58M | $4.00M | $2.93M | $3.27M | $2.90M | $2.53M | $4.05M |
| Long Term Debt | $9.27M | $12.11M | $13.90M | $16.76M | $19.63M | $23.55M | $23.41M | $23.31M | $23.18M | $22.99M | $59.65K | $146.98K | $231.43K | $313.98K | $395.31K | $458.29K | $490.35K | $521.69K | $552.33K | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $-1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $9.27M | $12.11M | $13.90M | $16.76M | $19.63M | $23.55M | $23.41M | $23.31M | $23.18M | $22.99M | $59.65K | $146.98K | $231.43K | $313.98K | $395.31K | $458.29K | $490.35K | $521.69K | $552.33K | $- |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $26.35M | $30.45M | $29.58M | $31.82M | $33.26M | $32.70M | $31.31M | $27.44M | $33.01M | $27.83M | $4.58M | $5.17M | $3.99M | $3.89M | $4.40M | $3.39M | $3.76M | $3.42M | $3.08M | $4.05M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $12.54K | $12.15K | $12.14K | $12.10K | $10.92K | $10.23K | $10.19K | $10.14K | $9.96K | $9.39K | $9.39K | $9.39K | $9.39K | $9.38K | $9.38K | $7.35K | $7.35K | $7.35K | $5.06K | $5.06K |
| Retained Earnings | $-182.11M | $-174.16M | $-163.43M | $-155.10M | $-144.50M | $-133.60M | $-122.75M | $-111.22M | $-101.56M | $-82.42M | $-75.00M | $-69.18M | $-60.70M | $-54.38M | $-47.42M | $-46.83M | $-43.79M | $-39.76M | $-35.85M | $-32.92M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $- | $-0 | $- | $- | $0 | $-0 | $- | $-0 | $0 | $- | $- | $0 | $0 | $- | $- | $- |
| Other Total Stockholders Equity | $201.10M | $196.15M | $194.34M | $192.28M | $170.62M | $158.08M | $155.19M | $152.22M | $145.55M | $129.47M | $126.41M | $125.04M | $123.90M | $122.23M | $120.41M | $71.20M | $70.91M | $70.78M | $52.86M | $52.81M |
| Total Stockholders Equity | $19.00M | $22.00M | $30.92M | $37.18M | $26.13M | $24.48M | $32.44M | $41.01M | $44.00M | $47.06M | $51.43M | $55.87M | $63.21M | $67.86M | $72.99M | $24.37M | $27.13M | $31.02M | $17.01M | $19.89M |
| Total Equity | $19.00M | $22.00M | $30.92M | $37.18M | $26.13M | $24.48M | $32.44M | $41.01M | $44.00M | $47.06M | $51.43M | $55.87M | $63.21M | $67.86M | $72.99M | $24.37M | $27.13M | $31.02M | $17.01M | $19.89M |
| Total Liabilities and Stockholders Equity | $45.36M | $52.45M | $60.50M | $69.01M | $59.39M | $57.19M | $63.75M | $68.45M | $77.01M | $74.89M | $56.00M | $61.04M | $67.20M | $71.75M | $77.39M | $27.76M | $30.89M | $34.45M | $20.09M | $23.93M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $45.36M | $52.45M | $60.50M | $69.01M | $59.39M | $57.19M | $63.75M | $68.45M | $77.01M | $74.89M | $56.00M | $61.04M | $67.20M | $71.75M | $77.39M | $27.76M | $30.89M | $34.45M | $20.09M | $23.93M |
| Total Investments | $- | $49.70B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $21.83M | $24.67M | $24.38M | $24.11M | $23.85M | $23.60M | $23.52M | $23.51M | $23.47M | $23.36M | $394.66K | $458.29K | $490.35K | $521.69K | $552.98K | $581.95K | $610.26K | $637.93K | $664.98K | $- |
| Net Debt | $-19.86M | $-25.08M | $-33.36M | $-42.53M | $-32.71M | $-30.65M | $-37.11M | $-41.69M | $-50.35M | $-48.28M | $-52.59M | $-58.42M | $-64.75M | $-69.22M | $-74.20M | $-24.46M | $-28.23M | $-32.83M | $-16.27M | $-21.04M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-37.61B | $-42.94M | $-40.85M | $-16.92M | $-14.85M |
| Depreciation and Amortization | $1.16B | $17.36K | $86 | $5.36K | $15.61K |
| Deferred Income Tax | $- | $-1.97M | $- | $- | $- |
| Stock Based Compensation | $6.85M | $7.61M | $5.20M | $4.11M | $452.29K |
| Change in Working Capital | $-5.75M | $-199.28K | $4.47M | $75.82K | $1.07M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-5.30M | $5.76M | $-90.12K | $-105.82K | $217.50K |
| Other Working Capital | $-453.77K | $-5.96M | $4.57M | $181.64K | $852.16K |
| Other Non Cash Items | $1.42B | $3.84M | $5.47M | $241.03K | $160.68K |
| Net Cash Provided by Operating Activities | $-35.03B | $-33.64M | $-25.71M | $-12.49M | $-13.15M |
| Investments in Property Plant and Equipment | $- | $-4 | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $-29.00M | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-29.00M | $- | $- | $- | $- |
| Debt Repayment | $-3.18M | $-59.30K | $25.00M | $- | $- |
| Common Stock Issued | $22.60M | $16.13M | $9.86M | $48.54M | $29.76M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $20.17B | $308.94K | $-568.87K | $344.12K | $70.46K |
| Net Cash Used Provided by Financing Activities | $20.19B | $16.38M | $34.29M | $48.89M | $29.83M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-14.87B | $-17.26M | $8.58M | $36.40M | $16.68M |
| Cash at End of Period | $41.69B | $56.56M | $73.82M | $65.24M | $28.84M |
| Cash at Beginning of Period | $56.56B | $73.82M | $65.24M | $28.84M | $12.16M |
| Operating Cash Flow | $-35.03B | $-33.64M | $-25.71M | $-12.49M | $-13.15M |
| Capital Expenditure | $- | $-4 | $- | $- | $- |
| Free Cash Flow | $-35.03B | $-33.64M | $-25.71M | $-12.49M | $-13.15M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-7.95M | $-10.73M | $-8.33M | $-10.60M | $-10.90M | $-10.85M | $-11.53M | $-9.66M | $-19.14M | $-7.42M | $-5.82M | $-8.47M | $-6.32M | $-6.96M | $-588.93K | $-3.05M | $-4.03M | $-3.91M | $-2.93M | $-3.99M |
| Depreciation and Amortization | $5.46K | $5.46K | $5.46K | $14.40K | $14.40K | $4.73K | $4.74K | $3.15K | $183.91K | $97.67K | $86 | $86 | $951 | $1.27K | $1.27K | $1.86K | $3.90K | $-37.90K | $45.70K | $3.90K |
| Deferred Income Tax | $- | $- | $- | $- | $232.59K | $- | $1.41M | $- | $- | $-97.67K | $- | $- | $-10.60M | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $1.64M | $1.78M | $1.80M | $1.63M | $1.35M | $2.07M | $2.11M | $2.08M | $1.37M | $1.34M | $1.35M | $1.13M | $1.67M | $1.70M | $441.60K | $293.37K | $131.42K | $129.79K | $56.28K | $134.79K |
| Change in Working Capital | $-2.24M | $628.44K | $-2.89M | $-1.25M | $400.69K | $1.04M | $4.16M | $-5.81M | $5.05M | $16.80K | $-1.51M | $915.20K | $83.88K | $68.97K | $1.03M | $-1.11M | $-854.22K | $2.50M | $-1.26M | $682.32K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $383.95K | $-1.95M | $-2.75M | $-981.99K | $1.62M | $951.66K | $2.34M | $852.77K | $-818.10K | $159.40K | $-867.72K | $1.44M | $-136.18K | $-929.78K | $1.42M | $-464.63K | $-144.37K | $467.06K | $-1.46M | $1.36M |
| Other Working Capital | $-2.62M | $2.58M | $-143.29K | $-267.37K | $-1.22M | $92.00K | $1.82M | $-6.66M | $5.87M | $-142.60K | $-640.80K | $-521.11K | $220.06K | $998.74K | $-392.74K | $-644.43K | $-709.85K | $2.03M | $203.87K | $-676.66K |
| Other Non Cash Items | $307.44K | $314.80K | $560.44K | $2.91M | $438.49K | $551.24K | $-957.55K | $193.21K | $5.00M | $170.40K | $60.17K | $60.26K | $10.66M | $60.26K | $60.26K | $60.26K | $116.33K | $60.00K | $-15.65K | $1.36M |
| Net Cash Provided by Operating Activities | $-8.23M | $-8.00M | $-8.86M | $-9.94M | $-8.46M | $-7.18M | $-4.81M | $-13.19M | $-7.53M | $-5.89M | $-5.92M | $-6.37M | $-4.50M | $-5.13M | $946.23K | $-3.80M | $-4.63M | $-1.25M | $-4.10M | $-3.16M |
| Investments in Property Plant and Equipment | $- | $-1 | $-29.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $- | $-1 | $-29.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Debt Repayment | $-3.14M | $-14.11K | $-13.79K | $-13.48K | $-13.17K | $-12.88K | $-12.59K | $-20.67K | $- | $25.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $3.17M | $-67.18K | $- | $19.49M | $10.48M | $815.20K | $243.74K | $4.59M | $9.86M | $- | $22.43K | $7.49K | $13 | $123.51K | $48.54M | $- | $17.79M | $17.79M | $- | $11.97M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $144.50K | $98.50K | $- | $531.09K | $300.09K | $- | $8.85K | $- | $-149.46K | $-449.33K | $22.43K | $7.49K | $13 | $123.51K | $220.60K | $- | $29.80B | $- | $- | $70.46K |
| Net Cash Used Provided by Financing Activities | $172.78K | $17.22K | $-13.79K | $20.01M | $10.77M | $802.33K | $240.01K | $4.57M | $9.71M | $24.55M | $22.43K | $7.49K | $13 | $123.51K | $48.77M | $- | $29.80B | $17.79M | $- | $12.04M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-8.06M | $-7.98M | $-8.90M | $10.07M | $2.31M | $-6.37M | $-4.57M | $-8.62M | $2.18M | $18.66M | $-5.90M | $-6.36M | $-4.50M | $-5.01M | $49.71M | $-3.80M | $-4.63M | $16.53M | $-4.10M | $8.88M |
| Cash at End of Period | $41.69M | $49.75M | $57.73M | $66.63M | $56.56M | $54.25M | $60.62M | $65.20M | $73.82M | $71.64M | $52.98M | $58.88M | $65.24M | $69.74M | $74.75M | $25.04M | $28.84M | $33.47M | $16.93M | $21.04M |
| Cash at Beginning of Period | $49.75M | $57.73M | $66.63M | $56.56M | $54.25M | $60.62M | $65.20M | $73.82M | $71.64M | $52.98M | $58.88M | $65.24M | $69.74M | $74.75M | $25.04M | $28.84M | $33.47M | $16.93M | $21.04M | $12.16M |
| Operating Cash Flow | $-8.23M | $-8.00M | $-8.86M | $-9.94M | $-8.46M | $-7.18M | $-4.81M | $-13.19M | $-7.53M | $-5.89M | $-5.92M | $-6.37M | $-4.50M | $-5.13M | $946.23K | $-3.80M | $-4.63M | $-1.25M | $-4.10M | $-3.16M |
| Capital Expenditure | $- | $-1 | $-29.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $-8.23M | $-8.00M | $-8.89M | $-9.94M | $-8.46M | $-7.18M | $-4.81M | $-13.19M | $-7.53M | $-5.89M | $-5.92M | $-6.37M | $-4.50M | $-5.13M | $946.23K | $-3.80M | $-4.63M | $-1.25M | $-4.10M | $-3.16M |
PDS Biotechnology Dividends
Explore PDS Biotechnology's dividend history, including dividend yield, payout ratio, and historical payments.
PDS Biotechnology News
Read the latest news about PDS Biotechnology, including recent articles, headlines, and updates.
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that three abstracts on Versamune® HPV (PDS0101) have been accepted for presentation at the 2025 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 30-June 3, 2025, in Chicago, Illinois.
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting
PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel Infectimune® based flu vaccine will be featured in a symposium on universal influenza vaccines at the American Association of Immunologists' IMMUNOLOGY2025™ Annual Meeting, taking place May 3-7, 2025, in Honolulu, Hawaii.
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that an abstract submitted by the National Cancer Institute (“NCI”) reporting clinical data on PDS01ADC, the Company's IL-12 fused antibody drug conjugate, has been accepted for presentation at the American Association for Cancer Research (“AACR”) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois.
PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - CEO Kirk Shepard - Chief Medical Officer Lars Boesgaard - CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright Mayank Mamtani - B.
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025.
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results
PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the year ended December 31, 2024, and provide a clinical programs update on Thursday, March 27, 2025, at 8:00 a.m.
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune ® platform candidate targets MUC1-positive solid tumors U.S. Patent #12,201,685 covering methods of using combinations of the Versamune ® platform and various immunocytokines, including PDS01ADC recently issued PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (“IND”) application filed in January 2025 to evaluate a combination of Versamune® MUC1 (formerly PDS0103), its novel investigational MUC1-targeted immunotherapy candidate + PDS01ADC to treat MUC1-positive unresectable, metastatic colorectal carcinoma (“mCRC”) in patients who failed previous treatment.
PDS Biotech Leadership to Participate in March Conferences
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, and the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025.
EMV Capital portfolio company PDS Biotechnology raises $11mln
EMV Capital plc (AIM: EMVC) portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) has raised $11 million, through an equity funding. PDS, which is focussed on immunotherapies, sold around 7.33 million new shares in a direct offer, plus warrants which (if exercised) will bring in another $11 million.
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced it has entered into securities purchase agreements with new and existing healthcare focused institutional investors as well as participation from certain directors of the Company, for the purchase and sale of 7,330,121 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 7,330,121 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules (the "Offering") at a combined purchase price of $1.50 for the institutional investors and $1.66 for certain directors of the Company.
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology
Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkpoint inhibitor naïve patients - mOS not yet reached Median OS of 17 months in HPV16-positive immune checkpoint inhibitor resistant patients; Historically published result is 3-4 months Significant tumor shrinkage with confirmed objective response rate (ORR) of 75% in HPV16-positive immune checkpoint inhibitor naïve patients; Historically published result is 11-24% PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of clinical results in the Journal of the American Medical Association (JAMA) Oncology.
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
Data confirms Versamune ® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025
PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat at the B.
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that on December 3, 2024, PDS Biotech granted nonstatutory stock options to purchase 7,000 shares of common stock to an employee in the clinical department as a material inducement to employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech.
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET
Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for PDS Biotechnology (PDSB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer Lars Boesgaard - Chief Financial Officer Kirk Shepard - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Ali Rashidfarrokhi - B. Riley Robert LeBoyer - Noble Capital Markets Operator Good morning ladies and gentlemen and welcome to PDS Biotech's Third Quarter 2024 Results and Clinical Strategy Update Conference Call.
EMV Capital highlights progress update from portfolio company PDS Biotech
EMV Capital (AIM:EMVC) has noted the clinical progress update from portfolio company PDS Biotechnology alongside its third-quarter update. Frank Bedu-Addo, PDS chief executive, said: "Since our last update in August, we have been actively engaged with investors and clinicians to discuss our strategy and funding requirements for our VERSATILE-003 Phase 3 trial of Versamune® HPV + pembrolizumab compared to pembrolizumab as a potential treatment for first-line recurrent/metastatic HPV16-positive head and neck squamous cell cancer (HNSCC).
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time
PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2024, and provide a clinical program update on Thursday, November 14, 2024, at 8:30 a.m. Eastern Time.
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune ® HPV combined with chemoradiation (N=8) 88% (15/17) of patients had a complete metabolic response IMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024
PDS Biotechnology: Continuing The Holding Pattern
PDS Biotechnology is focusing on an HPV-directed immunotherapy as its main near-term hope, with new data presented at the ESMO Congress. Strengths include promising clinical data and a focused pipeline, while risks involve typical biotech uncertainties and financial sustainability. The bottom-line summary suggests a cautious yet optimistic outlook, emphasizing the importance of upcoming clinical milestones and financial health.
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, will present updated data from the VERSATILE-002 trial evaluating first-line treatment with Versamune® HPV (formerly PDS0101) in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) during a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2024 on September 14, 2024, in Barcelona, Spain.
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City.
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will report financial results for the second quarter of 2024 and provide a business update on Tuesday, August 13, 2024, before the market opens. The press release will be available in the Investor Relations section of the Company's website at www.pdsbiotech.com.
PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)
PDS Biotechnology Corporation (NASDAQ:PDSB ) Clinical Program Update Conference Call August 1, 2024 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer Kirk Shepard - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Joseph Pantginis - H.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for PDSB.